Section 280E: The Tax Rule That Decides Whether a Dispensary Survives

Two dispensaries on the same street can post identical revenue and identical expenses, and one of them pays roughly triple the federal tax of the other.

The difference is not accounting skill. It is one sentence written into the tax code in 1982 to stop a convicted cocaine trafficker from deducting his business expenses, and cannabis has been living underneath it ever since.

This guide covers how Section 280E actually works, what it costs in real money, what April's rescheduling order changed, and who is still paying.

The sentence itself

Section 280E denies any deduction or credit for amounts paid or incurred in carrying on a trade or business that consists of trafficking in controlled substances prohibited by federal law.

Every word of that does damage. It is not a higher rate. It is the removal of the ordinary deductions every other business takes for granted. The IRS states plainly that a marijuana dispensary may not deduct advertising or selling expenses, and the same logic reaches rent, payroll for retail staff, marketing, utilities and security.

There is exactly one relief valve. Businesses may still reduce gross receipts by the cost of acquiring or producing the goods they sell, computed under the inventory rules of Section 471. The cost of goods sold survives because it is constitutionally required, not because Congress was being generous. Tax is imposed on income, and income has to mean something.

Why the rate goes past 100%

Run the arithmetic and the structure becomes obvious. A retailer with $10 million in revenue and $6 million in product cost has $4 million in gross profit. Suppose $3.5 million goes to rent, wages, compliance, security and everything else. Real profit is $500,000.

The IRS taxes the $4 million. At 21% federal corporate rate that is $840,000 in tax on $500,000 of actual earnings, an effective rate of 168%. The company loses money by operating profitably.

That is not a hypothetical edge case. It is the ordinary condition of cannabis retail, which is why the industry has a profitability problem that has nothing to do with demand. Analysis of the sector puts cannabis operators as having paid $2.24 billion in excess federal taxes during 2025 alone, with effective rates that can approach 70% or more, and more than $27 billion paid in federal taxes since 2018, of which around $15 billion was attributable to 280E.

Vertically integrated operators fare better, because more of their spending can be legitimately characterised as production cost instead of selling expense. A cultivator's labour goes into growing the product. A budtender's labour does not. That structural quirk is why so much of the American cannabis industry consolidated into vertical integration: not because it is efficient, but because it is the only lawful way to move expenses into a deductible category.

The number that explains the shakeout

The clearest way to see 280E is to look at what companies would have earned without it. Publicly traded operators disclose enough to reconstruct that.

Across 2023 to 2025 the industry carried around $9 billion in 280E tax expense. Company by company the reversal is stark. Green Thumb Industries posted 2025 net income of $114.2 million against an estimated $189.2 million without 280E. Trulieve reported a $116 million net loss where the counterfactual is a $30.4 million profit. Curaleaf's $201.9 million loss becomes $67.7 million.

Only 27.3% of American cannabis operators were profitable in 2024.

Some companies simply stopped paying. Several large operators took the position that 280E did not apply to them, filed amended returns, and claimed refunds running into the hundreds of millions. Others accrued the liability and did not remit it, leaving the eight largest multi-state operators carrying roughly $1.9 billion in unpaid tax, closer to $2.1 billion with interest and penalties.

The IRS has started coming for it. In May 2026 the government sued to claw back an $8.3 million refund from a multi-state operator that had claimed $64.2 million in deductions on an amended 2020 return, arguing the company was not entitled to deduct business expenses at all for that year.

What April 2026 changed

On April 23, 2026 the Justice Department placed FDA-approved marijuana products and medical marijuana subject to a qualifying state-issued licence into Schedule III, effective immediately.

Section 280E applies to Schedule I and Schedule II substances. Schedule III is outside it. So state-licensed medical cannabis is now, as a matter of federal tax law, a normal business that deducts normal expenses.

Adult-use cannabis was not rescheduled. It remains Schedule I, and it remains fully inside 280E.

That single distinction reorganises the economics of the entire industry. A medical-only operator in Florida or Pennsylvania just had its tax burden transformed. An adult-use retailer in California or Colorado did not. Dual operators now have to apportion.

Treasury addressed exactly that, announcing guidance to clarify that for businesses with multiple activities, 280E applies only to the activities related to trafficking in Schedule I or II substances, including by apportioning expenses. It also set a transition rule: rescheduling generally applies for a business's full taxable year that includes the effective date of the order.

That last sentence is worth more than it looks. A full taxable year including April 23, 2026 means the relief reaches back to January 1 for calendar-year filers.

The unexamined day is a wasted opportunity. Reflect on what you did, what you learned, and how you can improve.

John Dewey

What is still unresolved

Plenty.nBroader rescheduling of adult-use marijuana went to a DEA administrative hearing in summer 2026, with post-hearing briefs filed in August and no published timeline for a decision. Until that concludes, adult-use stays where it is.

The amended-return question is unresolved. Companies that claimed refunds for years when marijuana was indisputably Schedule I are now in litigation, and Treasury's guidance did not offer them a path. The clawback suits are testing whether those positions survive.

And 280E only ever mattered because of federal scheduling. It has no cannabis-specific text. If marijuana left the schedules entirely, the section would stop applying without a word of it being repealed.

What this costs the person buying

Every dollar of 280E ends up in the retail price, because it has nowhere else to go.

A retailer taxed on gross profit instead of net income must widen its margin to survive, and the customer pays that margin. Add state excise and local taxes on top and the legal price sits well above the unregulated one in most markets. That gap is the single best predictor of how much of a state's demand the legal market actually captures, and in most states the answer is well under half.

So the tax rule intended to punish traffickers has spent fifteen years subsidising them, by making the licensed alternative more expensive than the thing it was meant to replace.

There is one part of this economy that 280E never touched. A home grower in a state that permits cultivation pays no excise, no sales tax and no federal penalty, because there is no business and no sale. The plant does not know about the tax code.

That is the real arbitrage, and it is why yield per plant is worth thinking about carefully. Blue Gelato 41 produces 700 to 800 grams per square meter indoors from Blueberry crossed with Thin Mint GSC and Sunset Sherbert, and up to 3,000 grams outdoors from a single plant. Moby Dick, a deliberate cross of G13 Haze and White Widow made specifically to chase yield, runs 650 to 750 grams per square meter and 1,500 to 2,000 outdoors.

Breeding for yield is unfashionable next to breeding for flavour, and forty years in this trade has taught us it is the trait growers thank you for later. The cost per gram of a well-run grow is a rounding error next to a taxed retail shelf.

The short version

Section 280E denies cannabis businesses ordinary deductions, taxing them on gross profit instead of real income and pushing effective rates past 70% and sometimes past 100%. It has cost the industry roughly $15 billion in excess federal tax since 2018.

April's rescheduling moved state-licensed medical cannabis to Schedule III, which takes it outside 280E, with relief reaching back across the full taxable year. Adult-use cannabis was not rescheduled and is still paying.

The rule was written to stop drug dealers deducting expenses. Its main lasting effect has been to make the legal product more expensive than the illegal one.

Barney's Farm has been developing premium cannabis genetics since the 1980s, with over 40 Cannabis Cup wins. Explore our full seed catalog and find strains bred for every climate and skill level.